AU715546B2 - Phosphatase inhibitors and methods of use thereof - Google Patents

Phosphatase inhibitors and methods of use thereof

Info

Publication number
AU715546B2
AU715546B2 AU38205/97A AU3820597A AU715546B2 AU 715546 B2 AU715546 B2 AU 715546B2 AU 38205/97 A AU38205/97 A AU 38205/97A AU 3820597 A AU3820597 A AU 3820597A AU 715546 B2 AU715546 B2 AU 715546B2
Authority
AU
Australia
Prior art keywords
segment
compound
bivalent
compounds
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU38205/97A
Other languages
English (en)
Other versions
AU3820597A (en
Inventor
April Cunningham
John S. Lazo
Robert L. Rice
Peter Wipf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU3820597A publication Critical patent/AU3820597A/en
Application granted granted Critical
Publication of AU715546B2 publication Critical patent/AU715546B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU38205/97A 1996-07-30 1997-07-30 Phosphatase inhibitors and methods of use thereof Ceased AU715546B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/688530 1996-07-30
US08/688,530 US5700821A (en) 1996-07-30 1996-07-30 Phosphatase inhibitors and methods of use thereof
PCT/US1997/013408 WO1998004257A1 (en) 1996-07-30 1997-07-30 Phosphatase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
AU3820597A AU3820597A (en) 1998-02-20
AU715546B2 true AU715546B2 (en) 2000-02-03

Family

ID=24764793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38205/97A Ceased AU715546B2 (en) 1996-07-30 1997-07-30 Phosphatase inhibitors and methods of use thereof

Country Status (8)

Country Link
US (4) US5700821A (cg-RX-API-DMAC7.html)
EP (1) EP0959884A1 (cg-RX-API-DMAC7.html)
JP (1) JP3268782B2 (cg-RX-API-DMAC7.html)
AR (1) AR008120A1 (cg-RX-API-DMAC7.html)
AU (1) AU715546B2 (cg-RX-API-DMAC7.html)
CA (1) CA2261793A1 (cg-RX-API-DMAC7.html)
IL (1) IL128217A0 (cg-RX-API-DMAC7.html)
WO (1) WO1998004257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602713B1 (en) * 2001-02-09 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
US6465250B1 (en) 2001-02-09 2002-10-15 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit alpha expression
US20040121973A1 (en) * 2002-02-05 2004-06-24 Monia Brett P Antisense modulation of protein phosphatase 2 Catalytic subunit alpha expression
US7244622B2 (en) * 1996-04-03 2007-07-17 Applera Corporation Device and method for multiple analyte detection
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6277566B1 (en) * 1998-02-13 2001-08-21 Phillip A. Beachy Method for identifying a hedgehog-mediated phosphorylation state dependent transcription factor
JP2002512811A (ja) * 1998-04-27 2002-05-08 ユニバーシティー ヘルス ネットワーク 遺伝子スクリーニング法及び関連アッセイ法
US7051360B1 (en) * 1998-11-30 2006-05-23 United Video Properties, Inc. Interactive television program guide with selectable languages
US7238711B1 (en) * 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2000045852A1 (en) * 1999-02-03 2000-08-10 The Johns Hopkins University Method of treating cancer by restoration of pp32 function
WO2001010798A1 (en) * 1999-08-04 2001-02-15 Chemrx Advanced Technologies, Inc. Solid phase synthesis of oxa- and thiazoles
JP2003508049A (ja) * 1999-08-31 2003-03-04 ベーアーエスエフ アクツィエンゲゼルシャフト Ｃｄｃ２５の阻害物質を同定する方法
WO2001027077A2 (en) * 1999-10-12 2001-04-19 Basf Aktiengesellschaft Hydroxysulfonylalkylene-, phosphonoalkylene- or difluoro(phosphononon)methyl- substituted benzene, or benzofuran derivatives as non-peptidic cdc25 inhibitors
AU2001227812A1 (en) 2000-05-02 2001-11-12 Advanced Syntech, Llc A Kentucky Limited Liability Corporation A novel solid support template for preparation of highly functionalized heterocycle compounds
US20030027308A1 (en) * 2000-05-30 2003-02-06 Sugen Incorporated Novel human protein phosphatases identified from genomic sequencing
FR2812945B1 (fr) * 2000-08-10 2002-10-04 Aventis Pharma Sa Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules
US20040157306A1 (en) * 2000-11-13 2004-08-12 Sugen Incorporated Mammalian protein phosphatases
WO2002070680A1 (en) * 2001-03-01 2002-09-12 Basf Aktiengesellschaft Method of identifying inhibitors of cdc25
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
US20030124590A1 (en) * 2001-10-16 2003-07-03 Kosaku Uyeda Carbohydrate response element binding protein and uses thereof
WO2003042390A1 (en) * 2001-11-13 2003-05-22 Sugen, Inc. Mammalian protein phosphatases
WO2003078448A1 (en) * 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US20050074831A1 (en) * 2002-03-19 2005-04-07 Jasna Jerecic Interaction of NMDA receptor with protein serine threonine phosphatases
US20040023382A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of PPP3CB expression
US6828149B2 (en) 2002-06-20 2004-12-07 Isis Pharmaceuticals, Inc. Antisense modulation of PPP3R1 expression
AU2003255513B2 (en) * 2002-06-25 2007-07-26 Serono Genetics Institute S.A. Use of PP2A phosphatase modulators in the treatment of mental disorders
JP4464823B2 (ja) * 2002-10-02 2010-05-19 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒドロキシフェニルウンデカン誘導体、その製法、及びその使用
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102006033321A1 (de) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medizinische Verwendung von N-Phenylpropenoyl-Aminosäurederivaten und verwandten Verbindungen
KR100980328B1 (ko) * 2007-12-14 2010-09-06 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는트리아졸릴-티오-에타논 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암 예방 및 치료용조성물
JP5607025B2 (ja) 2008-04-21 2014-10-15 シグナム バイオサイエンシーズ， インコーポレイテッド 化合物、組成物およびそれらを作製する方法
CN119677737A (zh) 2022-04-22 2025-03-21 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
CN119454697B (zh) * 2025-01-07 2025-04-08 首都医科大学附属北京地坛医院 一种小分子化合物在制备抗肝损伤或抗肝纤维化药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583232A (en) * 1989-05-23 1996-12-10 Abbott Laboratories Retroviral protease inhibiting compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280034A (en) * 1991-08-23 1994-01-18 E. R. Squibb & Sons, Inc. Bis-heterocyclic prostaglandin analogs
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5770620A (en) * 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583232A (en) * 1989-05-23 1996-12-10 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
US5700821A (en) 1997-12-23
EP0959884A1 (en) 1999-12-01
WO1998004257A1 (en) 1998-02-05
JP3268782B2 (ja) 2002-03-25
EP0959884A4 (cg-RX-API-DMAC7.html) 1999-12-15
AR008120A1 (es) 1999-12-09
IL128217A0 (en) 1999-11-30
AU3820597A (en) 1998-02-20
US6040323A (en) 2000-03-21
US5856506A (en) 1999-01-05
US5925660A (en) 1999-07-20
JP2000515165A (ja) 2000-11-14
CA2261793A1 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
AU715546B2 (en) Phosphatase inhibitors and methods of use thereof
Wipf et al. Combinatorial synthesis and biological evaluation of library of small-molecule Ser/Thr-protein phosphatase inhibitors
CA2944198A1 (en) Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
JP2002524570A (ja) Ｍｄｍ２および５３間相互作用の阻害剤としてのピペラジン−４−フェニル誘導体
Abbenante et al. Regioselective structural and functional mimicry of peptides. Design of hydrolytically-stable cyclic peptidomimetic inhibitors of HIV-1 protease.
Fatima et al. Synthesis, molecular docking and xanthine oxidase inhibitory activity of 5-aryl-1H-tetrazoles
CA2402769A1 (en) Ceramide derivatives and method of use
RU2268262C2 (ru) Производные дигидронафталина и лекарственное средство, включающее указанные производные в качестве активного ингредиента
Chen et al. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1
Joyeau et al. N-Aryl 3-halogenated azetidin-2-ones and benzocarbacephems, inhibitors of. beta.-lactamases
Kozikowski et al. Synthesis, molecular modeling, 2-D NMR, and biological evaluation of ILV mimics as potential modulators of protein kinase C
Wang et al. Design, synthesis and anticancer activity of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-1, 2, 3-thiadiazoles as microtubule-destabilizing agents
JP5889987B2 (ja) ポリアミンの新規な蛍光誘導体、その製造方法、および癌性腫瘍の治療における診断手段としてのその使用
KR20150065718A (ko) 인돌린
US6307090B1 (en) Acylated oligopeptide derivatives having cell signal inhibiting activity
EP1163262B1 (en) Phenylalanine derivatives
US5538997A (en) 2,4-diamino-3-hydroxycarboxylic acid derivatives
US20100317831A1 (en) Probe compounds for protein tyrosine phosphatase (ptp) and precursors thereof
JP4594084B2 (ja) 非ペプチド性ｂｒｓ−３アゴニスト
Wipf et al. Synthesis and biological evaluation of a targeted library of protein phosphatase inhibitors
JPH07126286A (ja) 新規なペプチド誘導体
US7317030B2 (en) Compounds as inhibitors of cell proliferation and viral infections
CN120965805A (zh) 一种磷酸化拟肽类化合物及其医药用途
US20030207812A1 (en) Cd45 inhibitors
EP1718623B1 (en) Compounds as inhibitors of cell proliferation and viral infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired